Novel Hits for N-Myristoyltransferase Inhibition Discovered by Docking-Based Screening.

ABSTRACT: N-myristoyltransferase (NMT) inhibitors that were initially developed for treatment of parasitic protozoan infections, including sleeping sickness, malaria, and leismaniasis, have also shown great promise as treatment for oncological diseases. The successful transition of NMT inhibitors, which are currently at preclinical to early clinical stages, toward clinical approval and utilization may depend on the development and design of a diverse set of drug molecules with particular selectivity or pharmacological properties. In our study, we report that a common feature in the inhibitory mechanism of NMT is the formation of a salt bridge between a positively charged chemical group of the small molecule and the negatively charged C-terminus of an enzyme. Based on this observation, we designed a

SUBMITTER: Spassov DS 

PROVIDER: S-EPMC9457982 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature